Metmin

Mometasone furoate, the active ingredient in Metmin, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis and nasal polyps in adults and adolescents, reducing inflammation and improving nasal airflow.

GNH USA supplies Metmin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metmin (mometasone furoate) is a nasal corticosteroid used to manage inflammatory conditions of the nasal passages.

- Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Seasonal allergic rhinitis: controls symptoms triggered by seasonal allergens. - Nasal polyps: reduces polyp size and improves nasal breathing.

Metmin may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning - Headache - Nosebleeds (epistaxis) - Throat irritation or cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Adrenal suppression with prolonged high‑dose use

Before using Metmin, consider the following precautions.

- Active nasal infection: avoid use until infection resolves. - Glaucoma or ocular hypertension: monitor intra‑ocular pressure. - Concurrent intranasal steroids: limit combined exposure to reduce systemic effects. - Minimum effective dose: use the lowest dose for the shortest duration required. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metmin can interact with other medicines; review the following.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Systemic corticosteroids: additive immunosuppression risk. - Live vaccines: reduced vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., itraconazole): may modestly raise mometasone levels. - Ritonavir: potential increase in exposure. - St. John's wort: may decrease therapeutic effect.